

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNITED GENE HIGH-TECH GROUP LIMITED

聯合基因科技集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the Shareholders and potential investors that based on the preliminary review of the unaudited consolidated management accounts of the Group for the year ended 30 June 2013, the Group is expected to record a substantial decrease in turnover and continue to record a loss for the year ended 30 June 2013 as compared to that for the year ended 30 June 2012.

The information contained in this announcement is only a preliminary assessment by the Board based on the information currently available and the unaudited consolidated management accounts of the Group for the year ended 30 June 2013, which have not been reviewed, confirmed nor audited by the Company's independent auditors.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

This announcement is made by United Gene High-Tech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap.571, Law of Hong Kong) (the “**SFO**”).

Based on a preliminary review by the board of directors of the Company (the “**Board**”) of the unaudited consolidated management accounts of the Group for the year ended 30 June 2013, the Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Group is expected to record a substantial decrease in turnover and continue to record a loss for the year ended 30 June 2013 as compared to that for the year ended 30 June 2012. Based on the preliminary review of the relevant information currently available to the Company, such decrease in turnover was mainly attributable to a significant reduction in turnover in distribution of gene testing services and such loss was mainly attributable to impairment losses attributable to the tangible and intangible assets and continuing loss in business segments.

As the Company is still in the process of preparing and finalizing its annual results for the year ended 30 June 2013, the information contained in this announcement is only a preliminary assessment by the Board based on the information currently available and the unaudited consolidated management accounts of the Group for the year ended 30 June 2013, which have not been reviewed, confirmed nor audited by the Company's independent auditors. The actual annual results of the Group for the year ended 30 June 2013 may be different from what is disclosed in this announcement.

The annual results of the Group for the year ended 30 June 2013 are expected to be announced by the Company by the end of September 2013. Shareholders and potential investors are advised to read the annual results announcement of the Company carefully when it is published.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
United Gene High-Tech Group Limited
Lee Nga Yan
Executive Director

Hong Kong, 6 September 2013

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive director), Dr. Guo Yi (executive director), Ms. Xiao Yan (nonexecutive director), Ms. Wu Yanmin (non-executive director), Ms. Chen Weijun (independent nonexecutive director), Dr. Zhang Zhihong (independent non-executive director) and Mr. Wang Rongliang (independent non-executive director).